The Comptroller of Public Accounts readopts Texas Administrative Code, Title 34, Part 1, Chapter 13 (Unclaimed Property Reporting and Compliance), §13.3 (concerning Knowledge of Owner). The comptroller has reviewed §13.3 and determined that the reasons for initially adopting the rule continue to exist. Notice of any future amendments to this rule will be published in the Texas Register , as required under the Administrative Procedures Act, Government Code, Chapter 2001.

This review was conducted in accordance with Government Code, §2001.039. The proposed rule review was published in the March 19, 2004, issue of the Texas Register (29 TexReg 2927). No comments were received concerning the readoption of Chapter 13.

TRD-200601656

Martin Cherry

Chief Deputy General Counsel

Comptroller of Public Accounts

Filed: March 15, 2006

Title 22, Part 15

(Editor's Note: The Texas State Board of Pharmacy submitted a notice of adopted rule review that appeared in the February 24, 2006, issue of the Texas Register (31 TexReg 1315). The notice stated: "The Texas State Board of Pharmacy (Board) adopts the review of Chapter 309 (§309.1 and §309.8)..."; however, the phrase "(§309.1 and §309.8)" should have said "(§§309.1 - 309.8)." The corrected notice is republished in its entirety.)

The Texas State Board of Pharmacy adopts the review of Chapter 309, (§§309.1-309.8), concerning Generic Substitution, pursuant to the Texas Government Code §2001.039, regarding Agency Review of Existing Rules. The proposed review was published in the December 2, 2005, issue of the Texas Register (30 TexReg 8183).

The Board received written comments from the following: Abbott Laboratories, Inc.; American Thyroid Association; The Thyroid Foundation of America, Inc.; American Association of Clinical Endocrinologists; Richard Berger, M.D.; Lance Sloan, M.D.; Robert Talbert, Pharm. D., FCCP, BCPS, Division of Pharmacotherapy, College of Pharmacy, The University of Texas; Keith L Parker, M.D., Ph.D., Chief of Endocrinology and Metabolism, Southwestern Medical Center; Simona Scumpia, M.D., FACE, FRCP; and Kay R. Lewis, M.D., University of Texas Health Science Center at Houston. The written comments submitted recommended that the Board amend §309.3(e)(2) to include levothyroxine sodium as a narrow therapeutic index drug. The Board took no action based on the written comments.

The agency finds the reason for adopting the rule continues to exist.

TRD-200601570

Title 34, Part 3

In accordance with the §2001.039, Texas Government Code, the Teacher Retirement System of Texas (TRS) adopts the review of the rules in Chapter 53, relating to certification by companies offering qualified investment products under TRS's 403(b) program. The proposed notice of review was published in the October 7, 2005 issue of the Texas Register (30 TexReg 6449).

In conjunction with this review, TRS adopted amendments to §53.7. The amendments reduce the fee for certification by a company offering qualified 403(b) plan investment products from $5,000 to $3,000. TRS has determined that, with this change, the reasons for adopting the sections in Chapter 53 continue to exist. Accordingly, TRS readopts Chapter 53, as amended.

TRS received only one public comment in response to the notice of the proposed rule review as published in the above-referenced issue of the Texas Register . The Texas Department of Insurance complimented TRS for the apparent efficiency that TRS has achieved in administering the 403(b) program.

This concludes the review of Chapter 53, rules relating to certification by companies offering qualified investment products.

TRD-200601617

Ronnie G. Jung

Executive Director

Teacher Retirement System of Texas

Filed: March 14, 2006